Central nervous system (CNS) manifestations are not rare in pediatric rheumatic diseases. They may be a relatively common feature of the disease, as in systemic lupus erythematosus (SLE) and Behcets disease. Direct CNS involvement of a systemic rheumatic disease, primary CNS vasculitis, indirect involvement secondary to hypertension, hypoxia and metabolic changes, and drug associated adverse events may all result in CNS involvement. We have reviewed the CNS manifestations of SLE, Behcets disease, Henoch- Schonlein purpura, polyarteritis nodosa, juvenile idiopathic arthritis, juvenile ankylosing spondylitis, familial Mediterranean fever, scleroderma, sarcoidosis, Wegeners granulomatosis, Takayasus arteritis, CINCA syndrome, Kawasaki disease, and primary CNS vasculitis; and adverse CNS effects of anti-rheumatic drugs in pediatric patients. The manifestations are diverse; ranging from headache, seizures, chorea, changes in personality, depression, memory and concentration problems, cognitive impairment, cerebrovascular accidents to coma, and death. The value of cerebrospinal fluid (CSF) examination (pleocytosis, high level of protein), auto-antibodies in serum and CSF, electroencephalography, neuroimaging with computerized tomography, magnetic resonance imaging, SPECT, PET, and angiography depends on the disease. Brain biopsy is gold standard for the diagnosis of CNS vasculitis, however it may be inconclusive in 25% of cases. A thorough knowledge of the rheumatic diseases and therapy-related adverse events is mandatory for the management of a patient with rheumatic disease and CNS involvement. Severe CNS involvement is associated with poor prognosis, and high mortality rate. High dose steroid and cyclophosphamide (oral or intravenous) are first choice drugs in the treatment; plasmapheresis, IVIG, thalidomide, and intratechal treatment may be valuable in treatment-resistant, and serious cases.
Keywords: Central nervous system, rheumatic disease, neurologic, toxicity, treatment
Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Clinical Aspects and Therapeutic Perspectives of Relaxin
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Sexual Dysfunction among Women with Connective Tissue Disease
Current Rheumatology Reviews Systemic Sclerosis-Related Interstitial Lung Disease
Current Respiratory Medicine Reviews Glycolipids as Immune Modulatory Tools
Mini-Reviews in Medicinal Chemistry Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
Current Stem Cell Research & Therapy Regulation of TGF-β Signaling by SMADs and its Roles in Tissue Fibrosis
Current Signal Transduction Therapy Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design
Current Rheumatology Reviews Respiratory Tract Manifestations of Rheumatic Diseases in Children
Current Respiratory Medicine Reviews Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) An Unusual Presentation of a Rare Scleroderma Mimic: What is Behind the Scenes?
Current Rheumatology Reviews Sticking it to Scleroderma: Potential Therapies Blocking Elevated Adhesive and Contractile Signaling
Current Enzyme Inhibition New Treatment Options Using 5-HT3 Receptor Antagonists in Rheumatic Diseases
Current Topics in Medicinal Chemistry Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Pleural Involvement in Systemic Disorders
Current Drug Targets - Inflammation & Allergy Biologics in Systemic Sclerosis
Current Pharmaceutical Biotechnology Selenium and Autoimmune Diseases: A Review Article
Current Rheumatology Reviews Localized Scleroderma: A Clinical Review
Current Rheumatology Reviews Digital Ulcers in Systemic Sclerosis – How to Manage in 2013?
Current Rheumatology Reviews Endothelial Cell Aging and Apoptosis in Prevention and Disease: E-Selectin Expression and Modulation As A Model
Current Pharmaceutical Design